News
Klinische Phase-3-Studie LUNAR zeigt statistisch signifikante und klinisch bedeutsame Verlängerung des Gesamtüberlebens bei Patienten mit metastasiertem nicht-kleinzelligem Lungenkrebs nach platinbasierten Therapien
Novocure (NASDAQ: NVCR) stellt heute im Rahmen der Jahrestagung der American Society of Clinical Oncology (ASCO) 2023 positive Ergebnisse der klinischen Phase-3-Studie LUNAR zur Prüfung der
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Novocure (NASDAQ: NVCR) today is presenting positive results from the phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard therapies
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6th, at 10:00 a.m. CT
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Chemed Corporation to Present at the Jefferies 2023 Healthcare Conference
Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2023 Healthcare Conference on Thursday, June 8, 2023, at approximately 11:30 a.m. (ET) at the New
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer®, the ASCO Foundation, to advance cancer research and education.
Conquer Cancer is a global community of
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Acadia Healthcare to Participate in Jefferies Global Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Jefferies Global Healthcare Conference, June 7-9, 2023, in New York City.
In connection
Charles River Laboratories and Wheeler Bio Announce Agreement to Build and Operate RightSourceSM Laboratory
Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSource
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
ICON plc to Attend Upcoming Investor Conferences
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc